A history of device oversight by the US Food and Drug Administration traces regulatory changes in response to injuries caused by Dalkon Shield intrauterine devices.
AMA J Ethics. 2021;23(9):E712-720. doi:
10.1001/amajethics.2021.712.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
A nudge is an intervention designed to prompt a person to “voluntarily” make a choice intended by those who altered an environment or situation to yield that choice.
AMA J Ethics. 2020;22(9):E767-772. doi:
10.1001/amajethics.2020.767.
Stephanie L. Samuels, MD and Wilma C. Rossi, MD, MBE
When a parent resists a physician's recommendation for a pediatric patient, physician-parent partnering can promote the patient's best interest and help encourage lifestyle changes.
AMA J Ethics. 2018;20(12):E1126-1132. doi:
10.1001/amajethics.2018.1126
Clinicians can practice disability humility by developing social understandings of disability. This can help clinicians improve communication and express respect for patients’ authority about their experiences.
AMA J Ethics. 2018;20(12):E1181-1187. doi:
10.1001/amajethics.2018.1181